Webinar: Conquering Undruggable Targets to Obtain Preclinical Antibodies

Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped. Many targets have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. In this webinar, industry experts will share innovative strategies they have used to unlock challenging targets including membrane proteins.

We discussed:
- Key questions that scientists should ask before embarking on an antibody discovery campaign

- How to leverage advancements in immunization—including RNA—to target native epitopes and generate diverse antibodies

- Strategies for unlocking conserved antibody targets using approaches such as divergent host species

- Case studies of two challenging targets, claudin 6 and GPRC5D, with a focus on key innovations that led to the discovery of preclinical candidates including CTIM-76, a pre-IND (Investigational New Drug) stage molecule being developed for oncology therapeutics

Speakers: Martin Lehr, Joseph Rucker, Ross Chambers